Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies.
作者信息
Kudo Masatoshi
机构信息
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
出版信息
Liver Cancer. 2019 Nov;8(6):413-426. doi: 10.1159/000503254. Epub 2019 Sep 27.
Abstract
摘要
相似文献
1
Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies.肝细胞癌抗PD-1/PD-L1和抗CTLA-4抗体联合免疫治疗的科学原理
Liver Cancer. 2019 Nov;8(6):413-426. doi: 10.1159/000503254. Epub 2019 Sep 27.
2
Recent developments with immunotherapy for hepatocellular carcinoma.肝细胞癌免疫治疗的最新进展。
Expert Opin Biol Ther. 2018 Aug;18(8):905-910. doi: 10.1080/14712598.2018.1499722. Epub 2018 Jul 20.
3
Anti-PD-1/PD-L1 immunotherapy in conversion treatment of locally advanced hepatocellular carcinoma.抗 PD-1/PD-L1 免疫疗法在局部进展期肝细胞癌转化治疗中的应用。
Clin Exp Med. 2023 Jul;23(3):579-590. doi: 10.1007/s10238-022-00873-6. Epub 2022 Aug 26.
4
Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.使用免疫检查点抑制剂的癌症免疫疗法诱导的肝损伤的特征。
J Hepatol. 2018 Jun;68(6):1181-1190. doi: 10.1016/j.jhep.2018.01.033. Epub 2018 Feb 8.
5
Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma.晚期不可切除肝细胞癌的双重免疫检查点抑制剂或联合抗血管生成药物治疗。
Eur J Intern Med. 2023 May;111:37-46. doi: 10.1016/j.ejim.2022.12.025. Epub 2022 Dec 31.
6
Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy.联合抗细胞毒性 T 淋巴细胞相关抗原 4（CTLA-4）和程序性细胞死亡蛋白 1（PD-1）药物进行癌症免疫治疗。
Expert Opin Biol Ther. 2021 Dec;21(12):1623-1634. doi: 10.1080/14712598.2021.1921140. Epub 2021 May 4.
7
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).双抗 CTLA4 和 PD-1/PD-L1 阻断免疫疗法在癌症中的现状和未来；黑色素瘤和非小细胞肺癌 (NSCLC) 临床试验的经验教训。
J Immunother Cancer. 2018 May 16;6(1):39. doi: 10.1186/s40425-018-0349-3.
8
Combination therapy with PD-1 or PD-L1 inhibitors for cancer.PD-1 或 PD-L1 抑制剂联合治疗癌症。
Int J Clin Oncol. 2020 May;25(5):818-830. doi: 10.1007/s10147-019-01548-1. Epub 2019 Sep 23.
9
Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.放射治疗可增强免疫检查点抑制剂在小鼠肝癌模型中的抗肿瘤效果。
Oncotarget. 2017 Jun 20;8(25):41242-41255. doi: 10.18632/oncotarget.17168.
10
New insight in endocrine-related adverse events associated to immune checkpoint blockade.免疫检查点阻断相关内分泌不良事件的新认识。
Best Pract Res Clin Endocrinol Metab. 2020 Jan;34(1):101370. doi: 10.1016/j.beem.2019.101370. Epub 2019 Dec 11.
引用本文的文献
1
Severe immune-related adverse event colitis successfully treated with single-dose infliximab in an older adult with hepatocellular carcinoma receiving STRIDE therapy.在一名接受STRIDE治疗的老年肝细胞癌患者中，单剂量英夫利昔单抗成功治疗了严重的免疫相关不良事件结肠炎。
Clin J Gastroenterol. 2025 Aug 9. doi: 10.1007/s12328-025-02201-3.
2
Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors.使胃癌对免疫检查点抑制剂敏感的当前进展与未来方向
Cancer Med. 2025 Jul;14(14):e71065. doi: 10.1002/cam4.71065.
3
Immune Checkpoint Inhibition for Hepatocellular Carcinoma, Cholangiocarcinoma, and Combined Hepatocellular-Cholangiocarcinoma.免疫检查点抑制剂治疗肝细胞癌、胆管癌及肝内胆管癌合并肝细胞癌
World J Oncol. 2025 Jun;16(3):243-253. doi: 10.14740/wjon2571. Epub 2025 May 13.
4
Tremelimumab plus durvalumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the US payer perspective.从美国医保支付方角度进行的度伐利尤单抗联合曲美木单抗与索拉非尼用于不可切除肝细胞癌一线治疗的成本效益分析
BMJ Open. 2025 Apr 29;15(4):e090992. doi: 10.1136/bmjopen-2024-090992.
5
Efficacy and Safety of Ipilimumab Plus Anti-PD-1/PD-L1 Antibodies Combination Therapy in Advanced Hepatocellular Carcinoma Patients Progressing After Multiple Lines of Treatment: A Retrospective Multicenter Study.伊匹木单抗联合抗PD-1/PD-L1抗体治疗在经过多线治疗后进展的晚期肝细胞癌患者中的疗效与安全性：一项回顾性多中心研究
J Hepatocell Carcinoma. 2025 Mar 11;12:527-537. doi: 10.2147/JHC.S512302. eCollection 2025.
6
Quantitative evaluation of the efficacy and safety of first-line systemic therapies for advanced hepatocellular carcinoma.晚期肝细胞癌一线全身治疗的疗效和安全性的定量评估。
Eur J Clin Pharmacol. 2025 Mar;81(3):383-393. doi: 10.1007/s00228-024-03797-0. Epub 2024 Dec 28.
7
Early Clinical Outcomes of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: A Real-World Comparison with First-Line or Later-Line Treatment.度伐利尤单抗联合曲美木单抗治疗不可切除肝细胞癌的早期临床结果：与一线或二线治疗的真实世界比较
Drugs Real World Outcomes. 2024 Dec;11(4):701-710. doi: 10.1007/s40801-024-00458-7. Epub 2024 Oct 10.
8
Application of combined ablation and immunotherapy in NSCLC and liver cancer: Current status and future prospects.联合消融与免疫疗法在非小细胞肺癌和肝癌中的应用：现状与未来展望
Heliyon. 2024 Aug 14;10(16):e36388. doi: 10.1016/j.heliyon.2024.e36388. eCollection 2024 Aug 30.
9
Orbital Metastasis as the First Manifestation of Hepatocellular Carcinoma, and Its Effective Treatment with Combined Dual Immunotherapy: A Case Report and Review of the Literature.以眶内转移为首发表现的肝细胞癌及其联合双免疫治疗的疗效：病例报告及文献复习。
Am J Case Rep. 2024 Jun 3;25:e944002. doi: 10.12659/AJCR.944002.
10
Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?联合治疗克服肝癌免疫检查点阻断耐药：强强联手？
Semin Liver Dis. 2024 May;44(2):159-179. doi: 10.1055/a-2334-8311. Epub 2024 May 28.
本文引用的文献
1
Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial.阿维鲁单抗联合阿昔替尼作为晚期肝细胞癌患者的一线治疗：1b期VEGF肝脏100试验结果
Liver Cancer. 2021 Jun;10(3):249-259. doi: 10.1159/000514420. Epub 2021 Apr 7.
2
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.仑伐替尼联合帕博利珠单抗治疗不可切除肝细胞癌的 Ib 期研究。
J Clin Oncol. 2020 Sep 10;38(26):2960-2970. doi: 10.1200/JCO.20.00808. Epub 2020 Jul 27.
3
Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials.肝细胞癌的免疫肿瘤学疗法：现状与正在进行的试验
Liver Cancer. 2019 Jul;8(4):221-238. doi: 10.1159/000501501. Epub 2019 Jul 9.
4
Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway.仑伐替尼联合抗 PD-1 抗体治疗通过减少肿瘤相关巨噬细胞和激活干扰素通路来激活 CD8+T 细胞。
PLoS One. 2019 Feb 27;14(2):e0212513. doi: 10.1371/journal.pone.0212513. eCollection 2019.
5
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.帕博利珠单抗治疗索拉非尼治疗后晚期肝细胞癌患者（KEYNOTE-224）：一项非随机、开放标签的 2 期试验。
Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3.
6
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.利用抗血管生成药物增强癌症免疫治疗：机遇与挑战。
Nat Rev Clin Oncol. 2018 May;15(5):325-340. doi: 10.1038/nrclinonc.2018.29. Epub 2018 Mar 6.
7
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.纳武利尤单抗治疗晚期肝细胞癌患者（CheckMate 040）：一项开放标签、非对照、1/2 期剂量递增和扩展试验。
Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.
8
Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives.肝细胞癌的分子靶向药物：现状与未来展望
Liver Cancer. 2017 Feb;6(2):101-112. doi: 10.1159/000452138. Epub 2016 Dec 15.
9
Targeting neoantigens to augment antitumour immunity.靶向新抗原以增强抗肿瘤免疫力。
Nat Rev Cancer. 2017 Apr;17(4):209-222. doi: 10.1038/nrc.2016.154. Epub 2017 Feb 24.
10
Regulatory T cells in cancer immunotherapy.癌症免疫治疗中的调节性T细胞。
Cell Res. 2017 Jan;27(1):109-118. doi: 10.1038/cr.2016.151. Epub 2016 Dec 20.
Zotero 插件